Immune Netw.
2001 Aug;1(2):143-150. 10.4110/in.2001.1.2.143.
Study of plasma transforming growth factor-beta 1 level as a useful tumor marker in various cancers
- Affiliations
-
- 1Central Research I nstitute, Hanmi Pharmaceutical Co., Ltd., Dep artment of Thoracic and Cardiovas cular Surgery, Korea.
- 2Resp iratory Center, Yongdong Severance Hosp ital, College of Medicine, Yonsei University, Korea.
- 3Department of General Surgery, College of Medicine, Seoul National University, Seoul, Korea.
- 4Division of Oncology and Hematology, College of Medicine, Seoul National University, Seoul, Korea.
- 5Division of Gastroenterology, College of Medicine, Seoul National University, Seoul, Korea.
- 6Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea.
- 7Department of Obstetrics and Gynecology, Catholic University Medical College, Seoul, Korea.
- KMID: 2054225
- DOI: http://doi.org/10.4110/in.2001.1.2.143
Abstract
-
BACKGROUND: Many investigators have found transforming growth factor-1 (TGF-1) to be elevated in tumors. Changes in responsiveness to TGF-1 have been linked to malignant transformation, tumor progression and tumor regression. Many malignant cell lines of epithelial or hematopoietic origin are refractory to the antiproliferative effects of TGF-1. However, a little is known about the association of TGF-1 with progression of malignant tumor.
METHODS
In this study, we measured the plasma level of TGF-1 in various cancer patients and evaluated the utility of plasma TGF-1 as a possible tumor marker. Plasma TGF-1 levels were measured using enzyme-linked immunosorbent assay in cancer patients and normal controls. Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) as tumor marker were compared with TGF-1 in the aspects of sensitivity and specificity.
RESULTS
The mean of plasma TGF-1 levels was 1.2 19 +/-0.834 ng/ml in normal controls, 5.491 +/-3.598 ng/ml in breast cancer, 12.670 +/-10.386 ng/ml in lung cancer, 5.747 +/-3.228 ng/ml in hepatocellular carcinoma and 10.854 +/-7.996 ng/ml in cervical cancer. In comparison with CEA and AFP, TGF-1 is more sensitive.
CONCLUSION
We conclude that the high levels of TGF-1 are common in the plasma of cancer patients. These result s suggest that the plasma TGF-1 level can be a potent tumor marker in various cancer patients.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Expressions of transforming growth factor beta in patients with rheumatioid arthritis and osteoarthritis
- Plasma TGF-beta1 as a Tumor Marker in Breast Cancer Patients
- Significant fibrosis after radiation therapy in a patient with Marfan syndrome
- Expression of Transforming Growth Factor-alpha and Transforming Growth Factor-beta In Human Primary Lung Cancers
- Targeting the Transforming Growth Factor-beta Signaling in Cancer Therapy
